BIOMARCATORI IN NEUROLOGIA 1
19
1
Detecting amyloid and tau pathology in Parkinson disease, 4R-tauopathies and control subjects with plasma ptau217
2
Plasma Biomarkers of Alzheimer's Disease in Individuals with Subjective Cognitive Decline: a single-center experience
4
Distribution of Ischemic Stroke Etiologies According to TOAST Criteria in the last decade: are they changing?
5
Standardized protocol to search phosphorylated α-synuclein in skin biopsy: recommendations from an expert panel
6
Discordance of plasma pTau-217 levels with amyloid PET and CSF biomarkers in subjects with cognitive decline: a single center study
8
Exploring the phenotypic heterogeneity of Amyotrophic Lateral Sclerosis through blood biomarkers: a prospective study
9
Temporal Muscle Thickness as a Marker of Disease Progression and Functional Status in Amyotrophic Lateral Sclerosis
10
Quantifying synaptic dysfunction in multiple sclerosis by means of a cerebrospinal fluid biomarker panel
11
Plasma biomarkers and psycho-behavioral profile for characterization of psychiatric vs neurodegenerative diseases: insights from the NEMINAPSY cohort
12
Blood Biomarkers of Brain Damage in Transient Ischemic Attack: The role of plasma NfL and GFAP
13
Identifying Mild Cognitive and Behavioural Dysfunction in Amyotrophic Lateral Sclerosis provides key Prognostic insights
14
Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
15
Prognostic value of acute phase iMEPs for post-stroke spasticity
16
Subjective sleep dysfunction and daytime sleepiness are linked to resting-state EEG rhythms and cognitive performance in older adults with cognitive impairment due to Alzheimer's and Parkinson's disease
17
CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor fluctuations
18
Six-minute walking test as outcome measure of fatigability in SBMA
21
Dr.
22
Significant Elevation of Serum Pro-Inflammatory Cytokines in GBA1-Associated Parkinson's Disease: Implications for Immune-Mediated Pathogenesis
23
Kappa and Lambda Index as diagnostic and prognostic biomarkers in MS patients.
BIOMARCATORI IN NEUROLOGIA 2
20
334
SBMA Clinically Meaningful Change investigated for 6MWT and SBMAFRS
335
Detection of α-synuclein seeding activity in tears of Parkinson's disease patients using RT-QuIC
336
Distinct biological profile in oldest-old Alzheimer's Disease: the role of LDL-C on Blood-Brain Barrier function and disease burden
339
The impact of insulin resistance on cognitive impairment and CSF biomarkers in Alzheimer's disease
340
Occludin as potential predictor of outcome in acute ischemic stroke: preliminary results from the NIMBLE study
341
Anti-MOG Antibodies Titres Stratification in Adults with a First CNS Demyelinating Event: Clinical and Radiological Implications.
342
A case of cerebral cavernous malformations in a young patient with a rare CCM2 gene mutation (c.658_660 del, p. Val 220 del)
343
Frailty Index as a new marker of drug-resistance in adult people with focal epilepsy: a pilot study
344
The biomarkers' expert neurologist as a new specialist profile: a joint project of the University of Perugia and Perugia General Hospital
345
Blood biomarkers for prediction of Parkinson's Disease in GBA1 positive individuals
346
Cognitive decline and mortality in cerebral amyloid angiopathy related-inflammation: a single center longitudinal candidate predictor-finding study
347
Inflammation and Synaptic Plasticity in Parkinson's Disease: A Multicenter TMS Study
348
Which Biomarker-Based Diagnostic Algorithm for Functional Motor Disorders? Investigating Motor and Interoceptive Signatures Through Artificial Intelligence Analysis
349
Eye movements abnormalities during free-viewing task in frontal lobe syndrome: a biomarker for frontotemporal lobar degeneration?
350
Diagnostic performance of plasma pTau 217 and a three-zone threshold model for Alzheimer's disease: implications for reducing CSF testing
351
TMS-EEG unveils network dysfunction in early Multiple Sclerosis patients
352
Biomarkers of synaptic impairment and neuroinflammation in the Alzheimer's disease continuum
353
DETECTION OF MISFOLDED ALPHA-SYNUCLEIN BY RT-QuIC ASSAY IN OLFACTORY MUCOSA BRUSHING OF SUBJECTS AFFECTED BY NEURODEGENERATIVE DISORDERS
354
Blood Neurofilament Light Chains Assessed by Chemiluminescent Enzyme Immunoassay: Experience in a Large Cohort of Multiple Sclerosis Patients Treated with High- Efficacy Therapies and Correlation with Single Molecule Assay
355
Continuous Ofatumumab Treatment for Up to 7 Years Shows a Favourable Safety and Efficacy Profile in People With Relapsing Multiple Sclerosis
BIOMARCATORI IN NEUROLOGIA 3
19
638
Association of retinal layer thinning with intrathecal inflammation in early Multiple Sclerosis
639
Iron status or white blood cells count with relatives ratio: which is the best predictor in ischemic patient treated with rTPA?
640
The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and Frontotemporal dementia
641
OCT-Based Retinal Biomarkers in Parkinson's Disease: Exploring Early Diagnostic and Monitoring Potential
642
Diagnostic and Prognostic Value of Plasma Amyloidopathy, Tauopathy, and Neurodegeneration Biomarkers in a Real-World MCI Cohort
643
BIOLOGICAL EVIDENCE OF MULTIPLE PATHOLOGIES IN DIFFERENT NEURODEGENERATIVE DISEASES: CLINICAL-BIOLOGICAL CORRELATION
645
Total tau as a prognostic clue: neuropsychological profiles and potential outcome in Idiopathic Normal Pressure Hydrocephalus
646
Neurofilaments and Glial Fibrillary Acidic Protein levels in relation to response to treatment in Multiple Sclerosis
648
Sleep microstructure as an early marker of neurodegeneration in de novo Parkinson's disease: insights from a polysomnography study
649
Redox balance disruption in Alzheimer's Disease patients: findings from plasma and cellular biomarkers
650
NfL-Based Clustering Analysis in Biologically Defined Alzheimer's Disease According to the 2024 NIA-AA Criteria
651
ANTI-CD20 TREATMENT INDUCED NEUTROPENIA: A RETROSPECTIVE CASE SERIES
652
Aquaporin-4 cerebrospinal fluid levels are higher in Idiopathic Normal Pressure Hydrocephalus
653
The Diagnostic Value of Neurofilament Light in ALS and Its Mimics: a combined CSF and serum study
655
RT-QuIC DETECTION OF PATHOLOGICAL α-SINUCLEIN IN THREE CASES OF LATE ONSET ESSENTIAL TREMOR: A CASE SERIES
656
Clinical and biological characteristics of cerebral amyloid angiopathy, a case series
657
Brain-derived neurotrophic factor and Neurofilament light chain levels in multiple sclerosis patients treated with dimethylfumarate: a prospective observational study
658
Two Platforms, One Biomarker: Concordance of Simoa and Lumipulse NfL Assays in Alzheimer's Cerebrospinal Fluid.
659
Associations between CSF biomarkers and motor impairment measured by wearable sensors in cognitive decline
BRAIN HEALTH E NEUROEPIDEMIOLOGIA
14
276
EXECUTIVE AND WORKING MEMORY IMPAIRMENT IN YOUNG ADULTS WITH ISOLATED SEVERE HYPERTRIGLYCERIDEMIA: A CROSS-SECTIONAL STUDY
277
Neuropsychological Assessment in Obesity: Cognitive Vulnerability in Patients with Type 2 Diabetes Mellitus
278
Cognitive intervention with Go and Chess in Early and Subjective cognitive decline: the COGniChESs study results with a meta-analysis
279
Views on Brain Health in Solid Organ Transplant Candidates and Recipients
280
PREVALENCE OF COGNITIVE DECLINE POST STROKE: PRELIMINARY DATA FROM THE CIPS-TER STUDY
281
The effects of an immersive virtual reality and telemedicine-based multi-component intervention in individuals with subjective cognitive decline: study protocol of a randomized controlled trial
282
Innovative follow-up strategies: rationale, design and methodology of a telemedicine protocol in older patients affected by chronic diseases. Strat-AF Study
283
Risk and causes of hospitalization in persons with Parkinson's disease: The ParkLink Emilia-Romagna Region cohort
284
A POPULATION-BASED, RETROSPECTIVE, COHORT SYUDY BASED ON ADMINISTRATIVE DATA TO EVALUATE THE ASSOCIATION BETWEEN MODIFIABLE RISK FACTORS AND DEMENTIA:: the PREV-ITA-DEM study
285
Harmonization and pooling of information about modifiable risk factors for Alzheimer and other dementias: a systematic review of the Italian clinical cohorts
286
Binocular Diplopia as a Diagnostic Gateway to Neurological Disorders: A 19-Year Retrospective Study
287
Is it time to rethink Italian centers for cognitive disorders, based on insights coming from Lecanemab clinical trials? Preliminary data from the Fondazione IRCCS Istituto Neurologico Carlo Besta
288
Young-onset dementia in a Tertiary Memory Clinic: the experience in the Padova County
289
Longitudinally Extensive Transverse Myelitis in Seronegative Adults: Insights from a Case Report and a Systematic Review
CEFALEE 1
20
24
A Nomogram for the Prediction of Response to anti-CGRP mAbs: the CGRP Score
25
The Complex Decision of Initiating CGRP Monoclonal Antibodies in a Patient with a History of Ischemic Stroke due to Vertebral Artery Dissection.
26
Gender-related differences in response to long-term OnabotulinumtoxinA therapy in chronic migraine
28
Real-World Evidence of CGRP Dual Blockade: Clinical and Biomarker Insights from Combined Therapy in Chronic Migraine
29
Elettrophysiological effects of atogepant in episodic migraine: the ATOM project
30
Dysfunctional network for headache access in secondary and tertiary care
32
Super-responders (>75% response rate) to anti-CGRP monoclonal antibodies after one year of treatment: a multicenter, prospective, observational study
33
EXPLORING THE CENTRAL EFFECT OF ANTI CGRP-MONOCLONAL ANTIBODIES IN MIGRAINE PATIENTS: A RESTING-STATE FUNCTIONAL MRI STUDY
35
THE HEADACHE BURDEN IN A LARGE HIV POSITIVE SUB-SAHARAN AFRICAN POPULATION
37
EPTINEZUMAB FOR DIFFICULT-TO-TREAT MIGRAINE: WHO RESPONDS AND WHO NEEDS MORE
39
Visual hallucinations: a non-unique symptom
40
IMprovIng Distress pErception and mutuAlity in caRegivers (MI-DEAR study) of migraine patients with depressive symptoms treated with fremanezumab. An observational prospective real-life study to evaluate the effectiveness of fremanezumab for reducing the caregivers' burden and increasing reciprocity within the dyads.
41
Evaluating Atogepant’s Safety, Tolerability, and Effectiveness in Real-World Prevention of High-Frequency Episodic and Chronic Migraine: The GIANT Study
42
Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: an optical coherence tomography study.
43
Long Term Efficacy of Valproic Acid in a Case of PRRT2 Persistent Hemiplegic Migraine Aura
44
The Neglected Entity of Cluster Migraine. A Case Series
46
Is migraine a severity predictor in CADASIL patients? Early results from CADA-Migraine study
47
The Regional Outreach Programme of the International Headache Society: a WHO IGAP-oriented initiative in partnership with DREAM to improve healthcare for people with headache in sub-Saharan Africa
48
Effectiveness and Safety of Fremanezumab for Migraine Prevention Over 24 Months of Treatment: Final Analysis From the Italian Cohort of the PEARL Study
49
EEG recording during visual aura in migraine: results by quantitative analysis
CEFALEE E DOLORE 2
18
357
Focal Cerebral Hypoperfusion During the First Episode of Confusional Migraine in an Adult: A Case Report
359
Prompt diagnosis and multidisciplinary management of IIH promote favorable clinical and neuro-ophthalmologic outcome, avoiding invasive treatments.
360
Pain Catastrophizing in Chronic Migraine patients receiving Eptinezumab Treatment
361
Early Azathioprine as steroid-sparing therapy in Chronic Hypertrophic Pachymeningitis
362
Sumatriptan 85 mg / Naproxen Sodium 500 mg combination in the management of Menstrual Migraine: Two Case Reports
363
Familial Hypomagnesemia: A novel mutation of TRPM6 gene associated with severe migraine
364
Impact of Atogepant on Migraine Headache Severity for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the 12-Week ADVANCE and 52-Week Open-Label Trials
365
Impact of Atogepant on Activity Limitation in Participants With Episodic Migraine and Chronic Migraine: Post Hoc Analyses of ADVANCE, ELEVATE, and PROGRESS
368
Comparison of Cognitive Functions in Migraineurs with and without Osmophobia
369
Real-World Efficacy and Tolerability of Atogepant for Migraine Prevention: A Single Center Experience
370
Greater Occipital Nerve Block As An Add-On Therapy To Monoclonal Antibodies In Chronic Migraine: A Small Case Series
372
Survey on therapeutic efficacy and adherence in patients treated with Atogepant
374
Migraine natural history in women with breast cancer with hormone therapy.
376
Rimegepant as a Promising Treatment for Airplane Headache: A Case Report
377
Headache and brain fog are the most frequent and persistent symptoms in a cohort of neurological post-COVID-19 patients, regardless of the severity of the acute infection.
378
Gender Differences in Response to Long-Term Treatment with Botulinum Toxin Type A for Chronic Neuropathic Pain
379
UNLOCKING PAIN RELIEF: THE IMPACT OF BOTULINUM TOXIN ON MUSCLE FUNCTION IN TEMPOROMANDIBULAR DISORDERS
380
Facial Mimic Alterations in Trigeminal Neuralgia: a physiotherapy assessment
DEMENZA E INVECCHIAMENTO 1
20
102
Investigating Neuroinflammation in Frontotemporal Dementia: The Emerging Role of Galectin-3
103
Structuring the heterogeneity of Subjective Cognitive Decline: data-driven subtypes reveal distinct cognitive profiles, Alzheimer's disease biomarkers, and clinical trajectories
104
Anti-AK5 limbic encephalitis in a patient with pleural mesothelioma
105
Genetic determinants of cognitive health in the oldest population: protocol and descriptive cohort from the COOL study (Centenarians and oldest-olds in Liguria)
106
Frailty and young-onset cognitive decline: Fluid biomarkers and multimodal neuroimaging correlates in Mild Cognitive Impairment before age 65
107
Hippocampus and amygdala functional connectivity at rest in patients with Mild Behavioral Impairment due to AD
108
Klà¼ver-Bucy syndrome as onset presentation of extremely young onset behavioural variant frontotemporal dementia
110
Resting cerebral hemodynamics, vasomotor reactivity and neurovascular coupling in mild cognitive impairment and early dementia: a neurosonology study
111
Sex differences in brain metabolism and neuropsychological profiles in behavioral variant frontotemporal dementia
113
Visuoconstructive deficits in Huntington's, Parkinson's and Alzheimer's disease: A qualitative study
114
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium and evaluation Mini Mental test.
115
Addressing lipid-dependent resolution of inflammation in Alzheimer's disease via biochemical and computational methods
116
Early-phase AMY-PET versus FDG-PET in the diagnostic work-up of atypical Alzheimer disease: the AMY-ITA multicenter study
117
CHALLENGING THE BOUNDARIES: C9ORF72 MUTATION PRESENTING AS ALZHEIMER'S DISEASE
118
Alzheimer's Disease with incidental MAPT mutation: hidden phenotype or copathology?
119
Age-Related Differences in Cognitive Profile and CSF Biomarkers in Alzheimer's Disease
120
Pareidolia as diagnostic marker of prodromal Lewy Bodies Dementia
121
Primary lateral sclerosis mimicking corticobasal syndrome at onset: a case report.
122
The diagnostic challenge of slowly progressive autoimmune limbic encephalitis with Alzheimer disease copathology
123
Temporal lobe epilepsy mimicking a hippocampal amnestic syndrome suggestive of Alzheimer disease: the value of biological diagnosis
DEMENZA E INVECCHIAMENTO 2
20
429
Young-onset frontotemporal dementia with aphasia and Alzheimer-related copathology with a discordant CSF/PET amyloid status
430
Intranasal esketamine improves depressive symptoms and cognition in elderly patients with treatment-resistant depression
431
CHRONIC TRAUMATIC ENCEPHALOPATHY: A CASE REPORT
432
Longitudinal 18FDG-PET in Cerebellar Cognitive Affective Syndrome: Diagnostic and Prognostic Value
433
Cognitive decline and gait ataxia at the crossroad between autoimmunity and neurodegeneration: a case report and narrative review of literature
435
Astrocyte Reactivity in Alzheimer's Disease: Implications for Blood-Brain Barrier permeability
436
SMARTME&YOU HOME PLATFORM FOR MULTIMODAL MONITORING: INTEGRATING MOTOR ACTIVITY, SERIOUS GAMES, AND RESTING EEG IN OLDER ADULTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S AND PARKINSON'S DISEASES
437
The Impact of Caregiving in Frontotemporal Dementia: Key Predictors of Burden and Emotional Distress
438
A Case-Based Analysis of Cognitive and Cerebral Deterioration in CAA-related Inflammation
439
Comparative Evaluation of NIA-AA 2018 and 2024 Research Criteria for Alzheimer's Disease Diagnosis in a Real-World Clinical Cohort
440
White matter lesions in subjects with Subjective Cognitive Decline and Mild Cognitive Impairment: data from the Preclinical Cognitive Impairment Study in the Elderly (PreCISE)
441
Clinical Onset Patterns and Symptom Associations in prodromal Dementia with Lewy Bodies: a single-center retrospective study
442
Postoperative delirium (POD): preliminary results of risk assessment of the occurrence of POD in patients undergoing hip fracture surgery
443
Unlatching the brain: the essential role of medical services to shape differential neuropsychiatric diagnoses.
444
EYE TRACKING ASSESSMENT IN FRONTOTEMPORAL DEMENTIA (FTD): A CASE REPORT
445
Individualized Cognitive Stimulation Therapy in Neurodegenerative Disorders: Clinical Effectiveness and Predictive Factors
446
Exposure to traumatic brain injury and risk of frontotemporal dementia: a systematic review and meta-analysis
447
Preliminary impact of ketogenic and MCT-supplemented Mediterranean diet on cognition and function in MCI: results from the KETO-MIND (Ketogenic Diet and MCT SupplementatIon for Neurodegeneration Delay) trial.
448
Control Energy of Temporal Regions Relates to Tau Burden and Longitudinal Memory Decline in Preclinical Alzheimer's Disease
450
KINEMATIC AND NEUROPHISIOLOGICAL ANALYSIS OF HAND DEXTERITY IN HEALTHY SUBJECTS
DISORDINI DEL MOVIMENTO 1
26
248
OGA INHIBITION AS A POTENTIAL THERAPEUTIC APPROACH FOR TAUOPATHIES: THE PROSPER STUDY, A PHASE 2 TRIAL IN PSP
249
Effects of subcutaneous Foslevodopa-Foscarbidopa on motor and nonmotor symptoms in Parkinson's disease: a prospective longitudinal study
250
Assessing the feasibility, safety and efficacy of cerebello-spinal tDCS in MSA-C
251
Kinematic Gait Parameters to Describe and Detect Phenotype-Specific Alterations in Parkinson's Disease: Interpretative Hypotheses on the Freezing of Gait Phenomenon.
252
A rare occurrence of myoclonus-fixed dystonia syndrome
253
Digital bradykinesia Q-motor assessment in naà¯ve Parkinson's disease patients
254
Unsupervised Assessment of Motor Fluctuations in Parkinson's Disease: A Cross-Sectional Study with Wearable Sensors and Diaries
255
ACCELERATED THETA-BURST STIMULATION OF THE DORSOLATERAL PREFRONTAL CORTEX IN HUNTINGTON'S DISEASE: A PLACEBO-CONTROLLED EEG STUDY
256
Premature Ovarian Insufficiency as a Potential Risk Factor for Parkinson's Disease in Young Women
258
The overlooked symptom: Pain in Multiple System Atrophy and Parkinson's disease
259
CLINICAL AND NEUROIMAGING PREDICTORS OF OUTCOME AFTER DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE
260
Non-motor symptoms impact on different domains of supervised and unsupervised mobility in Parkinson disease.
261
The relation between upper limbs action tremor asymmetry, midline tremor and gait disorders in Essential Tremor: an exploratory study
262
“Dozing off" in the car and Excessive Daytime Sleepiness (EDS) in Parkinson's disease
263
JITTER AND SHIMMER AS POTENTIAL ACOUSTIC MARKERS OF DYSARTHRIA IN PARKINSON'S DISEASE: A PILOT STUDY
264
Motor, nonmotor and cognitive predictors of early treatment‑related motor fluctuations in Parkinson's disease patients
265
Diabetic Striatopathy: a rare complication of long poorly treated Diabetes
266
Clonidine for the management of crises in Stiff-Person syndrome
267
Efficacy and Safety of Omaveloxolone for Friedreich Ataxia: Four-Months Real-Life Data on Twelve Patients
268
Monitoring Levodopa responsiveness in Parkinson's Disease using mobile health technology: the Digital Levodopa Challenge
270
Long-Term Safety of Magnetic Resonance–Guided Focused Ultrasound in Movement Disorders – A Comprehensive Review of Outcomes
271
VISUAL DAT-SCAN INTERPRETATION OUTPERFORMS SEMI-QUANTITATIVE ANALYSIS IN A BENIGN TREMULOUS VARIANT OF PARKINSON'S DISEASE: A ‘PSEUDO-SWEDD' CASE
272
From clinical overlap to distinctive signatures in Atypical Parkinsonism: a multilevel analysis of cognitive, neuropsychiatric, and brain FDG-PET features
273
Cognitive impairment and neuropsychiatric symptoms in GBA-related Parkinson's Disease: a systematic review and meta-analysis
274
Safinamide add-on to levodopa therapy leads to complete disappearance of levodopa-induced dyskinesias in mid-stage Parkinson's disease: a case report
275
Advanced therapies for Parkinson's disease: Parkinson Unit AOU Careggi Firenze experience with subcutaneous Foslevodopa-Foscarbidopa therapy in Parkinson's Disease
DISORDINI DEL MOVIMENTO 2
27
531
Trunk acceleration-derived gait indexes and symmetry metrics describe the gait abnormalities of subjects with trunk lateral postural abnormalities in subjects with Parkinson's disease
532
Subcutaneous foslevodopa/foscarbidopa for advanced Parkinson's diseases: the experience of the Verona Parkinson Centre
534
Subcutaneous infusion of foslevodopa/foscarbidopa: the importance of a standardized assessment, preliminary data from a Movement Disorders Centre in Southern Italy
535
Atypical parkinsonism mimicking prion diseases: diagnostic challenges and predictive clinical features from the Italian Creutzfeldt-Jakob disease and related disorders Registry
536
Parkinsonism-hyperpyrexia syndrome due to gastroparesis rescued with subcutaneous Foslevodopa: a Case Report.
537
Expanding the Phenotypic Spectrum of ATP1A3-Related Disorders: insights from three atypical cases
538
Adult-onset Movement Disorder associated with a pathogenic CACNA1C Variant: extending the clinical spectrum
539
Anti-IgLON5 Encephalitis with Coexisting Chorea and Sleep Apnea: A Case with Distinct FDG PET/CT Findings
540
Posterior Cortical Hypometabolism in Two Siblings with GBA1 Mutations: Divergent Clinical Phenotypes
541
A case of anti-IgLON5 disease with a complex presentation mimicking other movement disorders.
542
Negative Myoclonus Following Immune Checkpoint Inhibitor Therapy in a Patient with Lung Adenocarcinoma: Expanding the ICI-Toxicities Spectrum
543
Biomarker-Based Diagnostic Algorithm for Functional Motor Disorders: investigating Motor, Exteroceptive, and Interoceptive Domains Through Artificial Intelligence Analysis
544
Effectiveness of Opicapone Added to Different Levodopa Doses in Parkinson's: Post-Hoc Analysis of the ADOPTION Trials
545
Sensory Inhibition and Descending Pain Modulation Deficits in Functional Motor Disorders
546
Wearable sensors may detect subtle gait and postural alterations associated with autonomic dysfunction in patients with early Parkinson's disease
547
A Novel Pathogenic Variant in the SLC6A8 Gene Presenting as Isolated Adult-Onset Dystonia in a Female: A Case Report
548
Under pressure: acute emotional reactivity reflected in Subthalamic Beta Oscillations in Parkinson's Disease.
549
Seronegative Chorea as a Rare Immune-Related Neurological Adverse Event Induced by Nivolumab: A Case of Multisystem irAE with Divergent Therapeutic Response
550
Steroid-Responsive Benign Hereditary Chorea: A Case of Unexpected Therapeutic Benefit
551
Continuous subcutaneous infusion of Foslevodopa/Foscarbidopa in patients with idiopathic Parkinson's Disease: understanding psychiatric adverse effect
552
Motor Fluctuations are associated with impaired postural control in Parkinson's Disease Patients: a severity-matched mobile health technology analyses
553
The presence of dyskinesia is associate with worse gait and balance in Parkinson's Disease
554
CONCOMITANT HETEROZYGOUS VARIANTS IN PINK1 AND EIF4G1 IN PARKINSON'S DISEASE: A CASE REPORT
555
Congenital cerebellar ataxia in a patient with SCA13: a case report
556
A challenging diagnosis of FXTAS: clinical, radiological, and therapeutic insight
557
ISOLATED GENERALIZED CHOREA IN A PATIENT WITH SMALL-EXPANDED ALLELE SPINOCEREBELLAR ATAXIA 17
558
Effects of Kinesio-Taping on patients with Parkinson's disease and Pisa syndrome: a prospective randomized, controlled trial
DISORDINI DEL MOVIMENTO 3
27
808
Hand dexterity in Parkinson's disease: a study with a sensorized-glove
809
Evaluating Beta-Sensing for the Optimization of Deep Brain Stimulation in Parkinson's Disease
810
Baseline variables associated with apomorphine sublingual film retention in Parkinsonian patients with motor fluctuations
811
Oropharyngeal adverse events in people with Parkinson's disease and motor fluctuations treated with apomorphine sublingual film
812
Sustained Long-Term Safety and Tolerability of Foslevodopa/Foscarbidopa in Parkinson's Disease: 96-Week Primary Treatment Period Results from an Ongoing Open-Label Extension Study
813
Painful legs and moving toes syndrome
814
Quantitative assessment of Nigrosome-1 volume, area and susceptibility in Parkinson's Disease
815
The role of Frailty in Adult Onset Focal Dystonia: a cross-sectional study
816
Effect of STN vs GPi Deep Brain Stimulation on Dysphagia in Parkinson's Disease
817
Chiari Malformation Type I Presenting with Cognitive Impairment and Parkinsonism: Temporary Reversal Following Epidural Blood Patch
818
Tonic Convergence Spasm as an Early Indicator of Pineal Tumor: A Case Report
819
Clinical-Radiological Differences in Hyperkinetic Movement Disorders associated with Acute and Chronic Cerebrovascular Disease.
820
Differential effect of dopaminergic treatment on bradykinesia features and limb-kinetic apraxia in Parkinson's disease
821
Visual and oculomotor deficits in Parkinson's Disease patients.
822
When Parkinsonism Deceives: A Case of Leukodystrophy Masquerading as PSP
823
Cognitive performances are associated with subclinical gait and postural alterations in early cognitively unimpaired patients with Parkinson's disease
824
From seizure to asterixis: a neurosurgical case report.
825
Long-Term Quality of Life after Subthalamic Deep Brain Stimulation for Parkinson's Disease: experience from a single center.
826
The hidden face of hypomimia in Parkinson's disease: exploring clinical motor and non-motor symptoms correlates
828
Identification of possible phenotypes in Parkinson's disease through machine-learning and motion analysis
829
Implementation of sub-cutaneous foslevodopa-foscarbidopa in advanced Parkinson's disease: experience in real-life
830
Impact of Opicapone and Foslevodopa/Foscarbidopa on sleep quality and mobility in Fluctuating Parkinson's Disease: preliminary insights from a longitudinal pilot study.
831
The effect of subcutaneous foslevodopa/foscarbidopa on non-motor symptoms and non-motor fluctuations
832
Expanding the clinical phenotype of GBA-associated parkinsonism: a case report
833
Cluster Analysis of Patient Characteristics Associated with Up to 100% "Off" Time Improvement from Two Phase 3 Trials
834
Outpatient management of Parkinson's Disease patients with continuous subcutaneous infusion of Foslevodopa/foscarbidopa
835
Chronic Pain in Parkinson Disease: Comparative Efficacy of Advanced Therapies
EPILESSIA 1
20
290
LPDs Redirect the Diagnostic Path in Structural Epilepsy: A Process Unfolding at 3 cm/sec
291
EEG: An Unexpected Tool for Diagnostic Precision in Cardiogenic Syncope
292
Efficacy and tolerability of Perampanel as only add-on in people with intellectual disability: data from the PEROC study
294
PERampanel effects on seizures and SLEEP quality in patients with epilepsy: PER-SLEEP, a prospective multicenter study
296
Feasibility study on the use of pre-implantation magnetoencephalography to identify predictive biomarkers of response to vagus nerve stimulation in patients with drug-resistant epilepsy (PREVEDeRE)
297
Cenobamate for new-onset refractory and super-refractory status epilepticus: a report of four cases
298
First Seizure Event in Modena: Characteristics of Adolescents and Adults Observed in 2023
299
Short- and long-term efficacy of Intravenous Brivaracetam as treatment in Refractory and Super-Refractory Status Epilepticus
300
Real-World Use of Fenfluramine in patients with Lennox-Gastaut Syndrome
301
EEG changes during pregnancy and association with clinical course of epilepsy
302
Focal epilepsy with sensory seizures associated with arginine:glycine amidinotransferase deficiency: A clinical and advanced magnetic resonance imaging study
303
Looking for Tonic Head- and cycling-seizures in idiopathic generalized epilepsy (IGE): a new potential marker for sodium channel blocker responsiveness?
304
Sleep disturbances in late-onset epilepsy of unknown origin: a questionnaire-based controlled study
306
Verbal production- induced epileptiform abnormalities in a patient with previous structural non-convulsive status epilepticus
307
Cenobamate effectiveness and safety in an Italian cohort of people with epilepsy: second interim results from the BLESS observational study
308
The Colored Pad Test: A Safe and Reliable Provocative Technique for functional/dissociative Seizures
309
The role of Perfusion CT in the acute diagnosis of SMART Syndrome
310
Phenotypic Variability in a southern Italian family with 16p13.2 GRIN2A deletion
311
An unusual electroencephalogram pattern in anti-Glutamic Acid Decarboxylase encephalitis. A case report and review from the letterature
312
Clinical Outcomes of Cenobamate Use in Drug-Resistant Temporal and Extratemporal Epilepsy: Experience from a Tertiary Epilepsy Clinic
EPILESSIA 2
18
560
Focal Epileptogenic lesion in a patient with Epileptic Encephalopathy secondary to SRCAP gene. Double pathology or linked disorders?
561
CJD micking NCSE: can the ictal genesis of epileptiform abnormalities always be ruled out? EEG features and discussion of a case report
562
The Impact of Vagus Nerve Stimulation on the Most Disabling Seizures: A Retrospective Study in Adults with Drug-Resistant Epilepsy
563
Prognostic Stratification of Status Epilepticus: a descriptive analysis of EMSE, STESS and SACE scores in a Neurology cohort
565
A prick is enough! Therapeutic drug monitoring of antiseizure medication through capillary microsampling devices
566
Don't fall for it: a misdiagnosed case of paroxysmal leg stiffness.
567
Improving epilepsy management in sub-Saharan Africa primary care: a tool to facilitate EEG reporting from remote
568
Clinical, Laboratory, and EEG Predictors of Outcome in Status Epilepticus: A Retrospective Tertiary Center Study.
569
Treatment approaches in post-hypoxic myoclonus: a narrative review with expert opinion
570
Early Seizures and Early Status Epilepticus Following Acute Cerebrovascular Events: A Retrospective Study in a Stroke Unit Population
571
Acute Symptomatic Seizures and Early Status Epilepticus in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study
572
Novel CLN6 Variant in Autosomal Recessive Adult-Onset Neuronal Ceroid Lipofuscinosis with Drug-Resistant Epilepsy: Expanding the Phenotypic Spectrum
576
Status epilepticus in cerebral amyloid angiopathy-related inflammation: a case series
577
Efficacy and tolerability of Cenobamate: real-world experience from an Italian tertiary Center.
578
Beyond age: is it never too late for VNS?
579
Ketamine in Status Epilepticus: How Soon Is Now?
580
Is earlier better? One year cenobamate outcome in a large real world population
581
Long-term outcome and risk of epilepsy development in patients with acute symptomatic post-stroke seizures
EPILESSIA 3
14
836
Utility and limitations of home-made videos in differential diagnosis between functional seizures and other paroxysmal events. An Italian cohort study
838
SEVERE HYPOTHYROID ENCEPHALOPATHY IN A PATIENT WITH DOWN SYNDROME: A DIFFERENTIAL DIAGNOSIS FOR LOMEDS
839
Botulinum Toxin in Epilepsia Partialis Continua: case report and review of the literature
840
Paraneoplastic Anti-Ma2 Encephalitis Presenting with Non-Convulsive Status Epilepticus and Cognitive-Behavioral Syndrome: A Case Report
841
Acute symptomatic status epilepticus and subsequent pilomotor epilepsy: a case of Serratia marcescens meningoencephalitis
843
Cenobamate effectiveness in drug-resistant focal epilepsy: a single centre real-world observation
844
Post-ictal headache: a cohort-study on consecutive patients with epilepsy
845
Efficacy of Cenobamate in Refractory Focal Epilepsy: a case series of different etiologies
849
Closed-loop acoustic stimulation during sleep to reduce cortical excitability and epileptic activity: study protocol
850
EXPERIENCE OF CENOBAMATE IN A PATIENT WITH DOUBLE CORTEX
851
Neuropsychological Profile of Cenobamate: Evidence from a Real-World Cohort with Drug-Resistant Epilepsy
856
Epilepsy and Movement Disorders: One Gene, Multiple Faces. A case report of PRRT2-related disorder.
857
Beyond surgery: a new scenario in drug-resistant epilepsy?
858
OROTRACHEALINTUBATIONIN A PATIENTWITH FOCALEPILEPSYAND PNES
MAL. CEREBROVASCOLARI 1
22
220
Prosopometamorphopsia as a Manifestation of Symptomatic Epilepsy after Stroke affecting the Face-selective Network: a Case Report
221
ADVANCED ULTRASOUND IMAGING TECHNIQUES FOR MORPHOLOGICAL ASSESSMENT OF POSTERIOR CIRCULATION INTRACRANIAL STENOSIS
222
FIBRINOGEN DEGRADATION COAGULOPATHY: A MIRROR OF THROMBOLYSIS EFFECTIVENESS IN STROKE PATHOLOGY?
223
Risk factors of cerebral vasospasm after aneurysmal subarachnoid haemorrhage in different genders: a monocentric retrospective analysis
225
Demographic, neurological and neuroanatomical predictors of functional outcomes in stroke: A longitudinal assessment using machine learning
226
Effectiveness of intravenous thrombolysis in patients with lacunar ischemic stroke in a real-world setting
227
Drug-drug interactions in patients with ischemic stroke on treatment with oral anticoagulants: population-based data
228
The Neutrophil-to-Lymphocyte Ratio as a Predictor of Haemorrhagic Transformation and Functional Outcome: A Comparative Analysis Before and After 6 Hours in a Monocentric Study.
229
A Striking Angiographic Presentation of Primary CNS Vasculitis: A Case Report
230
Thalamic Stroke in a Young Adult: A Diagnostic Challenge
231
Dual Posterior Cerebral Artery (PCA): are two arteries better than one? A clinical case of a very rare but not negligible anatomic variant in stroke.
232
When the Brain Warns the Heart: Frontal Hypoperfusion Predicts Atrial Fibrillation After Stroke
233
Incidence, Associations, and Mechanisms of unexplained Early Neurological Deterioration after Thrombectomy in Stroke Patients
234
GENDER INEQUALITIES IN ISCHEMIC STROKE MANAGEMENT IN A COMPREHENSIVE ITALIAN HOSPITAL: A RETROSPECTIVE COHORT STUDY ON 9167 PATIENTS
235
Ischemic stroke: not just an old age problem, it is time for concrete actions. AOUC's 24-year experience with young ischemic stroke patients
236
Comparing DOACs and Warfarin for Secondary Stroke Prevention in Atrial Fibrillation: Insights from a Multicenter Cohort Analysis
237
THE ROLE OF POST STROKE INFLAMMATION IN ACUTE EEG ALTERATION
239
ALLOSTATIC LOAD AND HOMEOSTATIC IMBALANCE IN ACUTE ISCHAEMIC SYNDROME
241
Familial Cerebral Cavernous Malformation: case series followed at Vas Cog Clinic at Careggi Stroke Unit.
244
Early-Phase Fluid Diagnostic Biomarkers in Acute Ischemic Stroke: An Integrative Umbrella Review
246
Intracerebral Hemorrhage care bundle management, early hematoma expansion, and 30-days mortality: data from a prospective registry
247
Association between Lipoprotein(a), Cognitive Performance, and Cerebral Vascular Lesions in Older Patients with Atrial Fibrillation on Anticoagulant Therapy: Findings from the STRAT-AF Study (Stratification of Cerebral Bleeding Risk in AF)
MAL. CEREBROVASCOLARI 2
25
502
Ischemic stroke on DOAC and non-stenosing high risk carotid plaque: are we looking up?
503
Up-to-date data on the proportion of patients with ischemic stroke undergoing revascularization procedures. Insights from a population-based registry.
504
VERTEBROBASILAR VENTURE
505
INTRAVASCULAR LYMPHOMA MIMICKING STROKE: A PROPOSED DIAGNOSTIC ROADMAP FOR THE ACUTE SETTING
508
MECHANISMS OF DAMAGE IN ACUTE STROKE
510
Bilateral Retinal Vein Thrombosis and Cerebral Amyloidoma: Unraveling a Complex CAA-ri Case
511
Endovascular treatment in refractory cases of Idiopathic Intracranial Hypertension (IIH): the experience of the Stroke Unit of Modena
512
Novel heterozygous c.298_299insG variant in the HTRA1 gene in a patient with leukoencephalopathy and stroke recurrence: a case description
513
Ischemic Stroke as the Initial Presentation of Moyamoya Syndrome (MMS) in a Pediatric Patient with Sickle Cell Disease (SCD)
514
Snowballs in a spring day: a case report
515
Delayed Hematoma Expansion in Hemorrhagic Brain Metastases
516
Ischemic stroke with suspected intracranial vasculitis in antiphospholipid syndrome: a complex case of overlapping pathophysiology
517
Good fetal and maternal outcomes after subarachnoid hemorrhage in newly diagnosed Moyamoya disease: the importance of a multidisciplinary team approach
518
Childhood ischemic stroke caused by a large intracranial dissecting aneurysm: endovascular treatment and diagnostic challenges.
519
Acute Ischemic Stroke Due to Persistent Primitive Trigeminal Artery (PPTA) Occlusion: Diagnostic and Therapeutic Implications
520
MULTIPLEX-MULTILAYER NETWORK ANALYSIS AFTER INTRAVENOUS THROMBOLYSIS PREDICTS FUNCTIONAL OUTCOME AND TREATMENT-RELATED COMPLICATIONS IN ACUTE ISCHEMIC STROKE
521
An atypical case of Dejerine-Roussy SyndromeÂÂ
522
Posterior Circulation Vasculitis as an Atypical Manifestation of Lyme Neuroborreliosis: A Case Report
523
Voxel-Based Morphometry of Retinal OCT (VBM-OCT) in the spectrum of Cerebral β-Amyloidosis: Promising Preliminary Findings in Cerebral Amyloid Angiopathy
524
A spontaneous internal carotid artery dissection in a patient with TEK-associated multiple venous malformations: risk factor or incidental finding?
525
Cerebellar cavernomas mimicking brain metastases in a patient with previous breast cancer: a diagnostic and therapeutic challenge
526
Atypical Course of Perimesencephalic Subarachnoid Hemorrhage: Diagnostic and Management Challenges
527
INTERICTAL EPILEPTIFORM ACTIVITY IN A REAL-LIFE OF ACUTE STROKE PATIENTS WITHOUT SYMPTOMATIC SEIZURE: AN INDEPENDENT PREDICTOR OF POOR OUTCOME
528
Hemorrhagic transformation and stress hyperglycemia in minor stroke: a causal mediation analysis
530
Cerebral Amyloid Angiopathy-related inflammation presenting with SIADH : A case report
MAL. CEREBROVASCOLARI 3
26
779
Apraxic agraphia as clinical presentation of a thalamic monolateral venous infarction: a case report
780
Unilateral Visual Loss as the Initial Presentation of Fabry Disease: A Diagnostic Challenge
781
Recurrent Rheumatoid Meningitis: An Uncommon Stroke Mimic
782
Prediction Of Early Interictal Epileptiform Discharges (IEDs) In Acute Stroke: A Multivariate Approach
783
Cerebral amyloid angiopathy related inflammation without cerebral amyloid angiopathy: role of deep radiological characterization in atypical form
784
ASSESSMENT OF MALNUTRITION WITH BIOIMPEDANCE ANALYSIS (BIA) AND ITS PROGNOSTIC IMPACT IN PATIENTS WITH ISCHEMIC STROKE
785
Amiodarone-Induced Neurotoxicity Mimicking Acute Cerebrovascular Event: A Case Report.
786
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME LIKELY RELATED TO ALTITUDE EXPOSURE AND PHYSICAL STRESS. A CASE-REPORT
787
Prevalence of posterior circulation vascular abnormalities in patients with transient global amnesia: a single center observational study
788
Aneurysmal subarachnoid hemorrhage and its complications' monitoring and management: data from a real word setting
790
Diagnostic challenges in CNS vasculitis: insight from a case report
791
When Dizziness Raises Red Flags: A Case of Fibromuscular Dysplasia mimicking a Benign Vertigo
793
Cardiac fibroelastoma as a rare cause of ischemic stroke in a young woman:a case report.
794
CT Perfusion in acute cerebellar ischemic stroke (ACIS): a useful tool in the hyper-acute setting
795
Incidence of Post-stroke-Epilepsy and analysis of predictive factors in a Cohort of ischemic-stroke patients hospitalized at AOU S. Anna in Ferrara between 2017 and 2019.
796
Hypoxic Burden Index and its influence on lesion volume in Ischemic Stroke.
798
Cerebral Venous Sinus Thrombosis and Subdural Hygroma in a patient with Essential Thrombocythemia: therapeutic challenges
799
Right-to-left shunt screening to transcranial Doppler sonography in subjects with MRI features of small vessel disease: cross-sectional data from a large Italian clinical cohort
800
Post-operative cerebral fat embolism in a patient with a previously undiagnosed CADASIL
801
Stroke After the Bite: When Minor Trauma Meets a Major Shunt
802
Pulmonary embolism complications in patients with acute stroke: the experience of the Stroke Unit at the G. Martino University Hospital in Messina
803
A case of cerebral venous thrombosis in a patient on estrogen-progestin therapy with a mild thrombophilic pattern: therapeutic management and follow-up
804
The use of ultrasound in patients with Disorders of Consciousness: preliminary results
805
Movement disorders as rare presentation of acute vascular diseases: a case series
807 bis
Endovascular treatment versus best medical therapy in ischemic stroke due to distal to middle vessel occlusions: a meta-analysis
807
Risk factors for stroke in men and women: an epidemiological picture
MAL. DEL MOTONEURONE 1
18
201
Cognitive reserve as a predictor of cognitive decline in Amyotrophic Lateral Sclerosis (ALS): a longitudinal study
202
Clinical and Genetic Characterization of SPT Complex Variants in Amyotrophic Lateral Sclerosis
203
Cognitive Reserve in Amyotrophic Lateral Sclerosis: a 2-[18F]FDG-PET study on sex-related differences
204
Exploring End-of-life Practices in Amyotrophic Lateral Sclerosis: the Role of Advanced Care Planning and Palliative Care Activation.
205
Deltoid strength ratio: a new promising prognostic marker for the stratification of flail arm syndrome.
206
SUBJECTIVE COGNITIVE AND BEHAVIORAL SYMPTOMS IN ALS: TOWARD EARLIER DETECTION
207
GENETIC AND PHENOTYPIC MODULATORS OF COGNITIVE AND BEHAVIORAL IMPAIRMENT IN ALS
208
Rise of ALS Incidence in North East Tuscany: an Isolated Anomaly or a Sneak Peek into Future Trends?
209
Unrevealing the sequence of dysphagia progression in ALS: An event-based, FEES-driven staging approach
210
Phosphatemia is an independent prognostic factor in Amyotrophic Lateral Sclerosis
211
Neurochemical pathways are altered in ALS
212
Cognitive and brain metabolic signatures in ALS-FTD patients: a multimodal study.
213
Neutrophil Percentage-to-Albumin Ratio as a possible biomarker for Amyotrophic Lateral Sclerosis progression: insights from the PRO-ACT Database.
214
Cranial-Onset Axonal Neuronopathy: A Rare Motor Neuron Syndrome with Atypical Features
215
Unilateral Right Hemiplegia Due to Upper Motor Neuron Dysfunction- A Case Report of Mills' Syndrome
216
The epidemiology of Primary Lateral Sclerosis: results from a population-based cohort
218
A novel ALS-associated DCTN1 variant promotes TDP-43 aggregation in vitro
219
Patient Preferences and Adherence to Different Formulations of Riluzole in ALS: A Survey-Based Study
MAL. DEL MOTONEURONE 2
15
729
LONELINESS AND QUALITY OF LIFE IN ADULT SMA PATIENTS: THE EXPERIENCE OF THE PARMA CENTRE
730
Evaluation of the Potential Role of UCHL1 and GFAP as diagnostic and prognostic biomarkers in Motor Neuron Diseases
731
Cognitive and Behavioral Impairment may influence Shared Care Planning and Treatment Decisions in ALS: An observational single-center study
732
Exploring brain metabolic connectivity in ALS patients with C9ORF72 hexanucleotide expansion: a 2-[18F]FDG-PET study
733
Behavioural determinants of Social Cognition in Amyotrophic Lateral Sclerosis: a cross-sectional study.
737
Prognostic factors of post-tracheostomy survival in ALS: a multicenter study
738
Obstructive Sleep Apnea in Amyotrophic Lateral Sclerosis: diagnostic challenges and predictive modeling
739
MND-Chorea Overlap: a new entity?
740
Neuropsychological comparison between PLS and Predominant Upper Motor Neuron ALS at first evaluation in a tertiary ALS Center
741
An atypical case of rapidly evolving upper motor neuron disease, with two variants of uncertain significance found in the senataxin gene.
742
Composite serum and CSF biomarker index correlated with clinical features for predicting ALS progression: a multivariate analysis
743
Exploring the role of interleukin 18 and neuroinflammation in amyotrophic lateral sclerosis
744
A Planned Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with ALS
745
The establishment of the Italian ALS Coalition: Outline of the policy changes needed across Italy to improve the lives of People Living with ALS (PLWALS) and their caregivers
746
ANALYSIS OF VOCAL PARAMETERS IN ALS PATIENTS: A PRELIMINARY STUDY
MAL. NEUROMUSCOLARI 1
20
124
Effectiveness and Safety of Ravulizumab in Generalized Myasthenia Gravis (gMG): Updated Analysis From a Global Registry
125
ANALYSIS OF FACIAL MUSCLE INVOLVEMENT IN ADULT FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 PATIENTS THROUGH MAGNETIC RESONANCE AND ULTRASONOGRAPHIC ASSESSMENT
126
Steroid-Sparing Effect of Complement blockers and FcRn Inhibitors in Generalized Myasthenia Gravis: A Real-World Cohort Analysis
127
Effectiveness of thymectomy in Very Late-Onset Myasthenia Gravis: a single-center experience.
128
Transition from pediatric to adult care: one-year experience from a national reference centers for neuromuscular diseases network
129
The role of Whole-Exome Sequencing and methylation analysis in untangling complex Facioscapulo-humeral Muscular Dystrophy cases
130
Anti-complement therapy in myasthenia gravis: a single center real life experience
131
Correlation between clinical response and MuSK-Ab changes in patients treated with Rozanolixizumab
132
Anti-FcRn treatment for generalized Myasthenia Gravis: a real word experience with Rozanolixizumab in AChR-Ab and MuSK-Ab positive patients.
134
Single Breath Count Test in Remote and In-Person Monitoring of Respiratory Function in LOPD and NMDs – a single center study
135
Diet and lifestyle in patients with neuromuscular disorders and their impact on clinical parameters and quality of life: a narrative systematic literature review.
136
Long-term safety of givinostat in patients with Duchenne muscular dystrophy: results from an open-label extension study
137
Has respiratory function assessment higher responsiveness than motor functional evaluation to the positive effect of risdiplam in later-onset SMA patients? The experience of a long-term follow-up in two italian centers
138
Investigating the effect of meningococcal vaccination in patients with myasthenia gravis undergoing complement inhibitor therapy
139
Early real-life with Vutrisiran in ATTRv amyloidosis: a single center experience
140
A Real-Life Experience with Zilucoplan in AChR-seropositive Generalized Myasthenia Gravis
141
Could OrSAT help to improve the multidimensional care in spinal muscular atrophy advanced disease stage?
143
Esploring the role of Motor Unit Number Index (MUNIX) as a biomarker of disease progression in Myasthenia Gravis
146
One-Year Single-Center Experience with Efgartigimod in Anti-AChR Positive Generalized Myasthenia Gravis: From Clinical Response to Quality of Life
148
Orodispersible film formulation of Riluzole in ALS: Improving Adherence, Tolerabilty and Treatment Experience
MAL. NEUROMUSCOLARI 2
24
612
Refractory Myasthenia Gravis - clinical course and predictive factors in a large cohort of patients
613
Comparative Analysis of Paranodal Antibody Assays in Autoimmune Nodopathies: Diagnostic Accuracy and Inter-Laboratory Agreement
614
Limb-girdle muscular dystrophies: clinical characteristics of LGMD2A/R1 and LGMD2B/R2 patients from a single italian centre.
615
Efficacy and Safety of Rozanolixizumab Treatment Cycles in Patients With Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies
616
Effect of Rozanolixizumab on Bulbar and Respiratory Symptoms in Patients With Generalised Myasthenia Gravis: Post Hoc Item-Level Analysis of MycarinG
617
Responder and Minimal Symptom Expression Rates With Rozanolixizumab in Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies
618
Analysis of Long-Term Efficacy of Nipocalimab in Myasthenia Gravis: Open-Label Extension of the Vivacity-MG3 Trial
620
SCOLIOSIS IN SMA PATIENTS TREATED WITH DISEASE-MODIFYING DRUGS: A PRELIMINAR STUDY
621
Psychosocial and clinical profile of pediatric and adult patients with limb-girdle muscular dystrophy
622
Early and Sustained Response Over Time With Zilucoplan in Generalised Myasthenia Gravis: 120-Week Post Hoc Analysis of RAISE-XT
623
Sustained minimal symptom expression in generalised myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
624
Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: Post hoc analysis
625
Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
626
IL-6 Inhibitors in Refractory Generalized Myasthenia Gravis: a case Report and Literature Review
628
Rituximab treatment in Myasthenia Gravis: a window into one center experience.
629
Efgartigimod in IVIg refractory or intolerant in AChR-seropositive generalized Myasthenia Gravis
630
Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in Myotonic Dystrophies: a valuable screening tool for cognitive impairment
631
Patient-reported outcomes from a phase 3 study of givinostat in patients with Duchenne muscular dystrophy
632
Post-thymectomy myasthenia gravis with onset 2 years after thymoma removal: a case report and literature review
633
Patient preferences and experience with self-administration of rozanolixizumab in generalised myasthenia gravis
634
Efgartigimod as Rescue Therapy in Refractory Myasthenic Crisis: A Case Report
635
Does thymectomy have a role in treatment of pure ocular AChR-Ab+ non-thymomatous Myasthenia Gravis patients? A retrospective case-control study
636
EFGARTIGIMOD IN MYASTHENIA GRAVIS: A REAL LIFE SINGLE-CENTER EXPERIENCE
637
Prevalence and Predictors of Sleep Disturbances in an Italian Cohort of Patients with Myasthenia Gravis
MALATTIE DEGENERATIVE
18
710
The dual effect of cholesterol on cognitive functions in REM sleep behaviour disorder: a pilot study
711
A TREVISO DEMENTIA (TREDEM) REGISTRY CLINICAL CASE SHOWING A FRONTOTEMPORAL PHENOTYPE WITH GENETIC AND ELECTRON MICROSCOPY EVIDENCES OF CADASIL
712
The Impact of Antidopaminergic Medications on the Assessments of Function, Cognition, and Motor Features in Placebo-treated Patients in the PROOF-HD Study
713
Glymphatic system role in NPH management
714
The OLE Portion of the PROOF-HD Trial Shows Persistent Benefits of Pridopidine on Function, Cognition, and Motor in HD
715
Improvement of neurovascular coupling but not vasoreactivity after steroid treatment in a patient with Cerebral Amyloid Angiopathy-related Inflammation
716
Atypical presentation of Leber hereditary optic neuropathy mimicking optic neuritis: challenges in three patients
717
Reversible Hypercalcemic Encephalopathy Due to Vitamin D Intoxication: A Case Report
718
POLG mutation causing PEO and sensory polyneuropathy with a myasthenic-like onset
719
Beyond the Usual Suspects: Aceruloplasminemia as a Hidden Cause of Cognitive Impairment and Parkinsonism
720
A case of sporadic CJD presented with intestinal pseudo-obstruction: broadening the clinical spectrum of CJD.
721
Expanding the SPG11 Mutation Spectrum: A Case of Hereditary Complex Spastic Paraplegia with a Novel SPG11 Truncating Variant and 9p24.3 Deletion
722
Rapid Cognitive Decline In A Patient With Multiple Sclerosis: A Challenging Diagnosis Towards Subacute Sclerosing Panencephalitis
723
Atypical Ataxic-Spastic Syndrome with SYNE1 Variant Association
725
Frontotemporal dementia with C9orf72 mutation presenting with flail leg syndrome and bizarre psychosis
726
Choline Alphoscerate Attenuates Brain Atrophy and improves Behavioural symptoms in Mild Cognitive Impairment: One-Year Outcomes of the CARL Study
727
A progressive speech disorder: a challenging case
728
Probable Frontotemporal Dementia in Two Siblings from a Consanguineous Family: A Single Clinical Case with Concordant Diagnostic Findings
MIOPATIE
15
900
Bethlem Myopathy and Intracranial Aneurysms, segregation in a Family carrying a COL6A3 Gene Mutation.
901
INTERPLAY OF INFECTION ,LOCKING SYNDROME in LGMD-TNPO3 RELATED:EVIDENCE FROM A SPORADIC SLOWAKIAN PATIENT WITH NOVEL MUTATION.
902
Acute tetraparesis after immune checkpoint inhibitor therapy. It is not what it seems.
903
Blurring the Lines Between Oculopharyngeal Muscular Dystrophy and Oculopharyngodistal Myopathy: A Case Report and Literature Review
904
Myopathy in HIV-infected patient as a possible side effect of the antiretroviral therapy
906
Muscle MRI early sign in presymptomatic patients with Late-Onset Pompe Disease (LOPD)
907
The long way to diagnose a childhood-onset ophthalmoparesis: the discovery of a rare variant of HNRNPA2B1 gene
908
MELAS syndrome: a diagnostic pitfall A case report highlighting the challenges of early recognition
909
Rituximab as treatment of ocular myasthenia: a case report
910
Phenotypic Variability and Disease Progression in FLNC p.Ala193Thr-Associated Myopathy: A Family-Based Study with Longitudinal Follow-Up
911
COL6A2 Mutation and Cerebral Moyamoya-like Disease: A Case Suggesting a Shared Extracellular Matrix Pathogenesis
912
How Specific are “Myositis-Specific Antibodies"? The need for a comprehensive approach to avoid a misleading interpretation.
913
Facioscapulohumeral muscular dystrophy and dermatomyositis: a clinical case report
914
Inflammatory Myopathy Following Influenza Vaccination: A Case Report
915
A Complex Clinical Case in a Patient with Congenital Spastic Tetraparesis: Diagnosis of Relapsing-Remitting Multiple Sclerosis and Hereditary Myopathy with a Novel Variant in the ACTN2 Gene
NEUROFISIOLOGIA CLINICA
15
596
Role of Nerve Conduction Study in monitoring ATTRv patients
597
A novel combined Electroencephalographic approach for monitoring neurological complications in neonates with Surgically Treated Congenital Heart Disease
598
Continuous subcutaneous apomorphine infusion effects on primary motor cortex activity in people with Parkinson's disease
599
Risk of seizures during asleep neurosurgeries including intraoperative neurophysiological monitoring: a systematic review and meta-analysis
600
Symptoms and functional testing in morphologically defined small fibers neuropathy (SFN)
602
Studying Botulinum Toxin Diffusion in Spastic Patients Using High-Density Surface EMG: A Clinical and Electrophysiological Perspective
603
NEUROPHYSIOLOGICAL PREDICTORS OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE
604
The role of early motor cortex changes in Parkinson's disease progression: a 4-year longitudinal neurophysiological study
605
Clinical and electrophysiological correlates of Retrograde Cricopharyngeal Dysfunction (R-CPD) treated by EMG-guided Botulinum Toxin injection
606
TMS–EEG Signatures of Neurophysiological Motor Network Dysfunction in Multiple Sclerosis: Clinical and Prognostic Correlates
607
Electrocortical changes due to vibro-tactile stimulation in patients with cervical dystonia
608
PIVOTAL STUDY ON ULTRASOUND-BASED SARCOPENIA ASSESSMENT IN ACUTE STROKE PATIENTS
609
Differential patterns of TMS-evoked activation of the sensorimotor network following stroke: a case series
610
Transcranial Ultrasound Stimulation in Neurology: A Systematic Review and Qualitative Meta-Analysis of Preclinical and Clinical Studies
611
Short-term effects of continuous theta burst stimulation in treating a young patient affected by post-ischemic hemidystonia
NEUROGENETICA/MALATTIE RARE
12
762
Real-World Experience with Omaveloxolone Treatment in Friedreich's Ataxia
764
Complex dystonia with nodular heterotopias and paramagnetic brain deposits due to biallelic ARFGEF2 variants
766
Assessing the impact of Friedreich Ataxia in Italy: a stratified analysis based on patients' ambulatory status
767
Expanding the Phenotypic Spectrum of FAT2-Associated Disorders: An Italian Case Series
769
Validation of a PCR-Based Protocol for FCGR3A V158F Polymorphism in MOGAD and NMOSD-AQP4+ Patients: Toward Personalized Rituximab Therapy
770
Deep pheno-genotyping of NDUFV1-related mitochondrial disorder
771
Mitochondrial ataxia: the Italian experience
772
Transition from Pediatric to Adult Care in Duchenne Muscular Dystrophy: Experiences of Patients, Caregivers, and Healthcare Professionals
773
Case Report: Novel homozygous MAN1B1mutation in two Italians patients with Rafiq syndrome.
774
Recurrent acute necrotizing encephalopathy type-1 (ANE1) associated with a RANBP2 variant: a case report and brief review.
777
SPG7 p.A510V heterozygosity as a cause of adult-onset cerebellar ataxia without spasticity: longitudinal evidence from a sporadic case
778
SANDO syndrome in siblings: A familial case series of POLG-related disorder with variable age onset
NEUROIMMAGINI
19
179
How to develop brain-banking in Italy? A cutting-edge challenge for neuroscience
180
Pre-Stimulus Neural Dynamics Predict TMS Responses: The Role of Fractal Dimension and Oscillatory Activity
181
Development of Allele-Specific Gene-Silencing siRNAs for MPZ-D61N in CMT1B Neuropathy
182
PERIODIC AND APERIODIC ELECTROENCEPHALOGRAPHIC COMPONENTS DURING THE TRANSITION FROM QUIET WAKEFULNESS TO LIGHT SLEEP IN ALZHEIMER'S DISEASE PATIENTS WITH MILD COGNITIVE IMPAIRMENT
183
GAIT ANALYSIS IN PATIENTS AFFECTED BY LATE-ONSET POMPE DISEASE (LOPD)
184
AI and the Next Generation of Neurologists: A National Survey of Italian Residents
185
AI Systems for Accurate Staging and Monitoring of Alzheimer's Disease: The TRACE4ADâ„¢ Framework
186
MRI-BASED HEALTHY BRAIN AGING MODELS REVEAL SPECIFIC ATROPHY PATTERNS DRIVEN BY MULTIPLE SCLEROSIS ACCORDING TO AGE, SEX, AND AGE AT ONSET
187
HANDWRITING DIFFICULTIES IN PARKINSON'S DISEASE: TECHNOLOGICAL ASSESSMENT AND RESTING-STATE FMRI CORRELATES
188
Quantifying longitudinal microstructural tissue changes in MS lesions with a unified metric derived from multiparametric quantitative MRI
189
A Novel White Matter Tract-Based Index Links Brain Damage to Clinical and Cognitive Symptom in Multiple Sclerosis
191
LESION LOCATION AND FUNCTIONAL CONNECTIONS REVEAL COGNITIVE IMPAIRMENT NETWORKS IN MULTIPLE SCLEROSIS
192
SPATIAL GENE EXPRESSION AND FUNCTIONAL NETWORK ABNORMALITIES IN MULTIPLE SCLEROSIS: EXPLORING BIOLOGICAL INFLUENCE ON BRAIN FUNCTIONAL REORGANIZATION
193
The Hedgehog sign in the differential diagnosis of idiopathic normal pressure hydrocephalus
194
Brain morphometry correlates of GFAP and NFL in Parkinson's Disease
196
Multi-modal investigation of the role of brain gyrification in Alzheimer's disease
198
White matter tract density index predicts post-stroke acute severity
199
The role of T1-Weighted MRI Radiomics in Progressive Supranuclear Palsy Phenotypes
200
A rare case of inflammatory CLOCC in a young woman.
NEUROIMMUNOLOGIA E NEUROINFETTIVOLOGIA 1
20
451
Serological quantitative, qualitative and functional profiling and neurofilaments as biomarkers in autoimmune encephalitis with LGI1 and CASPR2 antibodies
452
First-Line Immunotherapy Alone Versus Immunosuppression in GAD Antibody-Associated Cerebellar Ataxia: A Clinical Case Series
454
Treatment with Allogeneic JCV-Specific T Cells in a Lung Transplant Recipient with PML: A Case Report
455
Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
456
Observed efficacy of efgartigimod in generalized myasthenia gravis across patient subgroups in the ADAPT-SC+ study
457
Efgartigimod Consistently Improved Health-Related Quality of Life in AChR-Ab+ Participants With gMG in IV and SC Trials
458
Limbic Onset of Neurosarcoidosis: a challenging Neurological diagnosis for a Systemic Disease
459
ICI-related Myositis/Myasthenia gravis: an overlap or not?
460
STAT 1 Immunodeficiency and HSV-1 Associated Encephalitis
461
Isolated Oculomotor Dysfunction as a Rare Presentation of Anti-GAD Antibody-Associated Neurological Disease
463
Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT
464
A case of Etanercept-induced myelitis after a long exposure to the treatment in a patient with rheumatoid arthritis.
465
Steroid-Responsive Encephalomyelitis Associated with Anti-SOX1 Antibodies and a Suspected Neurohypophyseal Tumor: A Case Report of an Unusual Paraneoplastic Presentation.
466
PACHYMENINGITIS AS AN ATYPICAL INITIAL MANIFESTATION OF RHEUMATOID ARTHRITIS: A CASE REPORT.
467
Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
468
Very late-onset AQP4-positive neuromyelitis optica associated with severe autoimmune hemolytic anemia and thrombocytopenia: a case report
469
“Beneath the Surface: Misdiagnosed PML in a Teclistamab-Treated Multiple Myeloma Patient"
470
Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT): a case report highlighting diagnostic pitfalls and appropriate management.
471
CLINICAL AND SEROLOGICAL FEATURES OF ACUTE DEMYELINATING ENCEPHALOMYELITIS (ADEM) IN CHILDREN AND ADULTS: A LARGE MULTICENTRIC RETROSPECTIVE STUDY
472
Validation of the MOG-AR score: a retrospective multicenter study
NEUROIMMUNOLOGIA E NEUROINFETTIVOLOGIA 2
17
878
A Potential Synergistic Role of AIRE and HLA in Neurological Autoimmunity
879
The supporting role of visual evoked potentials for the diagnosis of optic neuritis within the 2022 ICON criteria
880
Clinical characteristics and management of immunotherapy in seronegative myasthenia gravis: a systematic review of the literature.
882
EBV-related hemophagocytic lymphohistiocytosis: a rare case of acute cerebral involvement
883
Anti-PCA/Tr antibody detection in a case of rapidly progressive cerebellar ataxia: Potential added value of the in-house tissue-based assay testing
884
Anti-IgLON5 disease presenting with Mylohyoid muscle myorhythmia as the initial manifestation of IgLON5 autoimmunity: a case report
885
Sex differences in the humoral response to vaccine in multiple sclerosis a meta-analysis
886
Efficacy and safety of efgartigimod in a patient with refractory AChR-IgG-positive myasthenia gravis and coexisting multiple sclerosis
888
Giant Cell Arteritis and immune checkpoints inhibitor in Non-Small Cell Lung Cancer: a case report
889
Subacute enterovirus cerebellar syndrome in a young patient previously treated for lymphoma with Chimeric Antigen Receptor T-cell (CAR-T) therapy: a case report.
890
When the Eyes Lie: An Atypical Presentation of Miller Fisher Syndrome presenting as a Thyroid Eye Disease (TED)
892
Anti-titin antibody encephalitis mimicking a cerebrovascular disorder
895
Immunoadsorption as a Novel Strategy in Susac Syndrome
896
When Dementia Isn't Dementia: A case of Anti-Caspr2 Encephalitis Masquerading as Frontotemporal Dementia
897
Catastrophic Presentation of Giant Cell Arteritis
898
Hidden in plain sight: isolated neurosarcoidosis unveiled by the “trident sign"
899
Cerebellitis in a 20-year-old man: A possible role for Mycoplasma pneumoniae
NEUROLOGIA COGNITIVO COMPORTAMENTALE / NEUROPSICOLOGIA CLINICA
25
149
Empathy changes and increase in personal distress along time: a new neuropsychological biomarker for Alzheimer's Disease?
150
Assessing Social Cognition in ALS and Chronic Pain: Validation of the FACE Test
153
Beyond the left hemisphere: language impairments after right-hemisphere stroke more common than expected
154
BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA IN THE TREVISO DEMENTIA (TREDEM) REGISTRY
155
A low dimensional structure of behavioral and anatomical correlates in aphasia syndromes
156
Facial Emotion Analysis for Early and Differential Diagnosis of Neurodegenerative Disorders: A Neuropsychological Application of AI
158
Hippocampus-Cortical Structural Networks in the Progression of Cognitive Impairment: A Source-Based Morphometry Analysis in Alzheimer's Disease continuum
159
Frailty and cognitive-behavioral phenotype in young-onset Mild Cognitive Impairment: insights from a multicentric cohort
160
Psychological characterization of FND patients: a pilot study
161
Is there a relationship between cognitive decline, surgical interventions and general anesthesia? A pilot retrospective observational study based on neuropsycological assestment
164
Neuropsychological Correlates of Theory of Mind in Pediatric Onset Multiple Sclerosis
165
Discrepancies Between Caregivers and Patients Ratings of Impulse Control Disorders in Parkinson's disease: Lack of Awareness or Social Desirability Bias?
166
How subjective age relates with neurodegenerative diseases: an exploratory analysis among older adults with Parkinson's Disease
167
Longitudinal MRI Correlates of Cognitive Trajectories in Multiple Sclerosis: a multicenter study
168
Personality Disorders in subjects with Temporal lobe epilepsy and Functional Seizures
169
Effect of Immersive Virtual Reality Face-Name Memory Training on long-term associative memory in subjective cognitive decline: preliminary results.
170
The Contribution of Lifelong Cognitive Engagement and Physical Activity to Cognitive Resilience in Mild Cognitive Impairment
171
When the Heart Interferes with the Brain: Effects of Cardiac Surgery on Higher Cognitive Functions
172
POCD Heart-Brain complications: a neuropsychological and psychological assessment of cognitive deficits following Cardio-surgery PRIN 2022 (2022PEK8YY)
173
When Pituitary Dysfunction Mimics Delirium: A Complex Case of Neurobehavioural Symptoms in Panhypopituitarism
174
ACCEPTABILITY AND USABILITY OF HOME TELEMONITORING SMARTME&YOU VIDEOGAMES TO MONITOR COGNITIVE FUNCTIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE PATIENTS
175
Affective Processing Deficit in TBI: Influence of Emotional Valence and Familiarity
176
Efficacy and tolerability of desvenlafaxine in patients with anxious-depressive syndrome: evidence from 21 patients.
177
The relationship between sleep and subjective and objective congnitve decline in Multiple Sclerosis
178
Personality profile in SCA27B: a single case report
NEUROLOGIA ETA' EVOLUTIVA
8
494
EARLY PREDICTORS OF LONG-TERM CLINICAL OUTCOMES IN PEDIATRIC MULTIPLE SCLEROSIS: A 12-YEAR STUDY
495
Superficial white matter and cortical gray matter abnormalities in pediatric-onset multiple sclerosis and association with cognitive performance
496
Complete Epstein-Barr virus seropositivity in a cohort of Pediatric Onset Multiple Sclerosis: a comparison to other autoimmune diseases
497
Childhood migraine chronification: is there a role for prophylactic treatment?
498
Pediatric arterial ischemic stroke: a single center's experience
499
Expanding the RNF213 Phenotype: Very Early-Onset, Rapidly Progressive Moyamoya Disease with Poor Collateral Vessel Development in an Infant
500
Exploring Quality of Life in Pediatric Cerebral Palsy: Insights from Child Self-Reports and Parent Proxy-Reports questionnaires
501
Stroke-like episode relapse and concomitant exacerbation of autonomic and sensory neuropathy triggered by infection in pyruvate dehydrogenase complex deficiency
NEUROONCOLOGIA
12
582
Immune Checkpoint Inhibitors-Associated Optic Neuritis: The First Reported Case induced by Cemiplimab and a Review of the Literature
583
Intracranial and Skull Base Recurrence of Hepatocellular Carcinoma in a Liver Transplant Recipient: A Complex Neurological Case
584
Cervical myelopathy and brachial plexopathy: an atypical presentation of Anti-Ma2 syndrome
585
A case of Immune Checkpoint Inhibitor associated Encephalitis
586
Experimental prospective multicentral study to define brain toxicities in skull-base and sinonasal cancers after particle therapy.
587
An unusual case of sudden-onset psychiatric symptoms: a diagnostic challenge
588
Recurrent Extraspinal Myxopapillary Ependymoma with NTRK Fusion: A Case Report
589
Cognitive impact of Lorlatinib in advanced ALK positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) patients
591
Anti-NMDAR Encephalitis Associated with Immature Teratoma and Gliomatosis Peritonei: A therapeutic challenge
592
Posterior Reversible Encephalopathy Syndrome induced by Pazopanib: a case report
593
Epileptic Seizure Relapse as a Predictor of Radiological Recurrence in Primary Brain Tumors
595
Anti-GAD limbic encephalitis in a hospitalized 79-year-old woman after COVID-19 pneumonia: a case report
NEUROPATIE 1
19
313
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trials
314
Early Cardiac Sympathetic Denervation in Hereditary Transthyretin Amyloidosis (ATTRv): A Multimodal Evaluation with 123I-MIBG Scintigraphy and Peripheral Biomarkers
315
A case of progressive sensory-autonomic neuropathy
317
Impact of Prior Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses
318
Nerve ultrasound characterization of a cohort of anti-MAG neuropathy and CIDP patients: a retrospective study
319
Guillain-Barre syndrome and posterior reversible encephalopathy syndrome: two cases of a rare association.
321
Investigating Neuropathological correlates of Hyperactive and Psychotic symptoms in dementia, a systematic review
322
Unveiling neuroradiological and neurophysiological features in a novel proteolipid protein 1 (PLP1) related disorder
323
Multiple cranial nerves involvement as clinical onset of neurosarcoidosis
324
Bad taste as symptom at onset of IgM-related AL amyloidosis
325
Recurrent Painful Ophthalmoplegic Neuropathy: migraine variant or inflammatory cranial neuropathy?
326
When Brachial Plexopathy Hides Malignancy: A Literature-Informed Approach to Post-Radiation MPNST
327
Subacute dysphagia and hypophonia associated with anti-GM3 IgM antibodies: a case report
328
Sensory neuropathies selectively modify on-line body scheme representation
329
Polyradiculoneuropathies Associated with Immune Checkpoint Inhibitors: Are We Facing a New Nosological Entity?
330
A case of long-lasting tremor in a young male
331
Cranial nerve multineuritis as clinical onset of extramedullary relapse of acute myeloid leukemia
332
A case of Bickerstaff brainstem encephalitis with isolated serum anti-GM2 antibodies
333
Diagnosis and therapeutic management of Guillain-Barrà© syndrome in late twin pregnancy: a challenging clinical case
NEUROPATIE 2
19
473
Cardiomyopathy as an initial presentation of Hereditary Transthyretin Amyloidosis caused by mutation Val50Met: a case report
474
Hereditary sensory and autonomic neuropathy type II: a case report
475
Neuralgic Amyotrophy: a rare pediatric case associated with Claude Bernard Horner syndrome
476
Thunderclap headache, otoneurological symptoms and dysgeusia as atypical clinical manifestations of Guillain-Barrਠsyndrome: a case report
477
Efgartigimod in refractory multifocal motor neuropathy: a case report.
478
Thyrotoxic periodic paralysis and Migration: An Emerging Diagnosis in Western Countries
479
Post-Surgical painful sensorimotor axonal multineuropathy
480
A RARE CASE OF MORVAN SYNDROME WITH DUAL CASPR2 AND LGI1 ANTIBODIES REVEALING METASTATIC THYMOMA
481
ATYPICAL ONSET GUILLAIN-BARRà€° SYNDROME ASSOCIATED WITH PRIMARY CYTOMEGALOVIRUS INFECTION AND SEVERE NEUTROPENIA: FAVORABLE OUTCOME WITHOUT ANTIVIRAL THERAPY
483
Progression of Peripheral and Autonomic Nerve Dysfunction in Hereditary Transthyretin Amyloidosis
484
SUBACUTE IMMUNE-MEDIATED POLYNEUROPATHY RESPONDING TO ORAL PREDNISONE DURING LONG-TERM VEMURAFENIB THERAPY.
485
Cerebral visual impairment in a patient with Charcot-Marie-Tooth syndrome and Neurofibromatosis type 2: an uncommon case report
487
Post-traumatic painful trigeminal neuropathy (13.1.2.3 - ICHD-3) Following Misguided Gamma Knife Surgery: A Case of Diagnostic Oversight with Lasting Consequences
488
Peripheral Neuropathies Induced by Anti-TNF-α Therapies: Two Case Reports and a Systematic Literature Review
489
Efgartigimod as add-on treatment in refractory Guillain-Barrਠsyndrome: a case report.
490
Tropical ataxic neuropathy following raw cassava consumption: a neurophysiological perspective
491
A case of atypical Miller Fisher Syndrome with stroke-like onset
492
When the Diagnosis Remains Elusive: A Case of Subacute-Onset Chronic Polyradiculoneuropathy
493
An atypical case of Guillain-Barrà©
RIABILITAZIONE NEUROLOGICA E NEUROTRAUMATOLOGIA
9
748
Tandem position with eyes closed: clinical, cognitive and radiological insights for an easy and sensitive task for balance function in non-disabled patients with Multiple Sclerosis
750
Evaluation of the impact of experimentally induced fatigability on motor and cognitive functions in Multiple Sclerosis: a cross-sectional study
751
Clinical characteristics and urodynamic analysis of urinary dysfunction in multiple sclerosis: a single center study
752
Pain Relief in Patients < 55 and ≥ 55 Years With Spasticity Treated With OnabotulinumtoxinA: Results from the ASPIRE Study
753
Cognitive Rehabilitation Efficacy in Parkinson's Disease with Mild Cognitive Impairment: gender-related efficacy differences
754
Pain in Patients With Spasticity: Patient Characteristics From the Adult Spasticity International Registry (ASPIRE) Study
755
INNOVATIVE TECHNOLOGICAL APPROACHES AND THEIR USEFULNESS IN THE ACUTE SETTING: EXPERIENCE FROM THE TRIESTE STROKE UNIT
756
Can balneotherapy with ozone improve outcomes in patients with Aquired Brain Injury? Promising findinds from a quasi-randomized clinical trial
757
Extracorporeal shock wave therapy as a treatment for spasticity: Review
SCLEROSI MULTIPLA 1
22
50
Multiple Sclerosis from onset to secondary progression: a 30-years Italian register study
51
Combination of genetic, viral and environmental factors in the susceptibility to pediatric Multiple Sclerosis (Pedigree Study Group): a gene-environment risk score
52
Association of choroid plexus enlargement with intrathecal inflammation in early multiple sclerosis
54
Genetically predicted leucocyte telomere length correlates with age at onset in multiple sclerosis
55
Integrating genetic and phenotypic data from the PROGEMUS database and the Italian Multiple Sclerosis and Related Disorders Register
56
Exploring EEG Microstates as Biomarkers in Cognitive Impairment and Rehabilitation in Multiple Sclerosis
57
Choroid plexus enlargement in multiple sclerosis: normative trajectories, clinical correlates, and genetic associations
58
Subcutaneous Natalizumab Administration in Relapsing-Remitting Multiple Sclerosis: Results of EASIER 2 Study
59
Thought it was just fatigue? Think twice  it could be myelitis
61
Influence of oral and skin microbiota on Multiple Sclerosis risk and severity: a Mendelian Randomization analysis
62
Assessing Optic Nerve Involvement in MS: Accuracy of VEP, MRI, OCT and a Proposal for Combined Diagnostic Strategies.
63
Evaluation of the prognostic role of distance walking fatigability in a cohort of early non-disabled multiple sclerosis patients
64
Natalizumab Evaluation of Safety and Efficacy in the transition from intravenous and subcutaneous administration: a retrospective study (NEST-sc study)
65
Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Multiple Sclerosis
66
OCT and NfL: anticipating neurodegeneration in a non-invasive way
68
Effectiveness of a dance-based intervention on motor outcomes in young adults with multiple sclerosis: results of the ESPRIMO study
69
Effectiveness and safety profile of cladribine in the long-term in a monocentric real-world population of multiple sclerosis patients
70
Real life data of patients with multiple sclerosis treated with cladribine: serum neurofilament light chain dosage in clinical practice
71
A Multimodal Approach to Identify relevant biomarkers in MS: May we distinguish different phenotypes at the time of diagnosis?
72
Task-Oriented Virtual Reality Enhances Motor Network Connectivity in Progressive Multiple Sclerosis: A Randomized Trial
73
Evaluating the effectiveness of cladribine in secondary progressive multiple sclerosis: a study of the Italian MS Register
74
Impact of high-efficacy disease modifying treatments in pediatric-onset multiple sclerosis patients compared to adult-onset: a study from the Italian Multiple Sclerosis Registry
SCLEROSI MULTIPLA 2
23
75
Taste Function in Patients with Relapsing-Remitting Multiple Sclerosis: Preliminary Results.
76
Wearing-Off Effect as a Predictor of Disability Progression in Multiple Sclerosis: A Five-Year Follow-Up Study
77
Effectiveness and Tolerability of additional cycle of Cladribine in patients with Multiple Sclerosis: A Preliminary Real-World Cohort Study
78
Subcutaneous versus intravenous Natalizumab extended-interval dosing in pregnant women with MS: a French and Italian case series
79
Neutropenia in patients treated with anti-CD20 monoclonal antibodies for central nervous system inflammatory diseases: a single-center retrospective analysis
80
Reductions in anti-EBV antibodies during anti-CD20 treatment are not associated with clinical outcomes in multiple sclerosis
81
The Role of Retinal Hyper-Reflecting Foci in Axonal Damage and Retinal Vascular Density in Multiple Sclerosis
82
The impact of cognitive function on motor performance and dual-task ability in early non-disabled multiple sclerosis patients
83
Using plasma neurofilament light chain to evaluate response during cladribine treatment
84
Ofatumumab in Relapsing Multiple Sclerosis: Real-World Safety data and Implications for Early Intensive Treatment
85
Short washout from sequestering to depleting agents in multiple sclerosis is effective and safe: the FAST experience.
86
Comparing STRATIFY JCVTM DxSelectTM and IMMUNOWELLTM JCV Tests in RRMS to Assess PML Risk
87
Ublituximab use in a Real-World Setting: Rapid CD19+ B-Cell Depletion and Comprehensive Clinical Evaluation Beyond EDSS
88
Reassessing PML Risk in Multiple Sclerosis: Impact and Limitations of Anti-JCV Antibody Assay Selection
89
Olfactory Function and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis Patients
90
Neurofilament light chains in cerebrospinal fluid reflect grey matter pathology and intrathecal inflammation in early multiple sclerosis
92
Impact of visit density and magnetic resonance imaging monitoring on progression independent of relapse activity in relapsing multiple sclerosis
93
Predictive Factors of Response to anti-CGRP Monoclonal Antibodies in Patients with Multiple Sclerosis
94
Invisible decline: assessing disability in Multiple Sclerosis through wearable devices
95
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS
96
Ketogenic diet as additional and safe therapeutic tool in a very severe case of ADEM
98
Evaluation of Natalizumab biosimilar effectiveness based on prior treatment exposure: a retrospective analysis
99
Real-World Effectiveness of Ofatumumab in Relapsing Multiple Sclerosis: Single-Center Experience From a Large Italian MS Cohort
SCLEROSI MULTIPLA 3
24
381
Long term efficacy and safety of ocrelizumab in a real-world setting: a monocentric observational study
382
Applying the International Classification of Cognitive Disorders in Multiple Sclerosis (IC-CoDiMS) at Diagnosis: Insights from a Single-Centre Cohort
383
Instruments measuring (health-related) quality of life in people with multiple sclerosis: a systematic review following COSMIN guidelines
384
Transitioning from Natalizumab to Cladribine in Relapsing MS: Safety and Efficacy Considerations in a Real-World Cohort
385
Ublituximab exerts a rapid depletion of B and T Cell Depletion in Multiple Sclerosis Patients: preliminary results
386
Association between Cognitive Reserve, Fatigue and Quality of Life in Multiple Sclerosis: A Single centre Exploratory Cross-Sectional Study
387
SMarter: Multicentre, cross-sectional, observational, time-and-motion, real-world evidence study on the impact of the intravenous and subcutaneous formulations of ocrelizumab on the patient journey and healthcare system cost in multiple sclerosis
388
Cortical atrophy and cognitive outcomes in relapsing MS patients treated with ofatumumab: a real-world longitudinal study
389
Small Fiber Neurophaty in a Cohort of Multiple Sclerosis: the Fidenza MS Centre experience
390
Run in study on the safety and tolerability of a fasting-mimicking diet in relapsing remitting multiple sclerosis
391
SCLEROSIS AND CALCIUM
392
Marginal Zone-Like B Cells Drive Inflammation and Undergo Long-Term Depletion After Cladribine in MS
393
Epstein Barr Virus-specific T lymphocyte response in a case of “accelerated" multiple sclerosis onset
394
High risk of pneumonia in MS patients treated with antiCD20 mAbs: data from a real world cohort and correlation with lymphocyte subpopulations and immunoglobulin levels
395
Clinical disability predictors over the disease course in multiple sclerosis
396
Structural MRI predictors of cognition in Multiple Sclerosis: Evidence from a Multi-Site Cohort
397
A challenging case of EBV-positive CNS lymphoma in a multiple sclerosis patient: case report and systematic review of the literature
398
Anti-GFAP Astrocytopathy: A Rare Inflammatory CNS Disorder Presenting as Meningoencephalitis and Polyradiculoneuritis
399
Atypical demyelinating disease differential diagnosis through Advanced MRI: From Suspected ADEM to Confirmed MS
400
Dynamics of choroid plexus volume in multiple sclerosis patients treated with hematopoietic stem cell transplantation
401
Autologous haematopoietic stem cell transplantation affects leptomeningeal enhancement in multiple sclerosis: a longitudinal study
402
Two Siblings, Two Diagnoses: A Familial Case of MS and AQP4-Positive NMOSD
404
Neurofibromatosis type 1 associated Multiple Sclerosis: a case series with focus on neuro-ophthalmological findings
405
A rare case of Leukodystrophy-Like Progressive MS in Adulthood: Unravelling a Diagnostic Dilemma
SCLEROSI MULTIPLA 4
24
100
Safety and Efficacy of Frexalimab in Participants with Relapsing Multiple Sclerosis: 2.5-Year Results From the Phase 2 Open-label Extension
101
Paramagnetic Rim Lesions as a Prognostic Biomarker in the Tolebrutinib Phase 3 Trials for Disability Outcomes
407
Pathological characterization of broad rim lesions (BRLs): a new biomarker for rapid progressive multiple sclerosis
408
Longitudinal OCT assessment of retinal changes in RRMS patients treated with Ofatumumab
409
John Cunningham Virus (JCV) Serostatus Discrepancy Between Two Different Tests: Impact on Clinicians' and Patients' Choices in a Cohort of Multiple Sclerosis Patients Treated with Natalizumab
410
Managing the Unexpected: A Case of Unplanned Pregnancy During Ponesimod Therapy in Multiple Sclerosis
411
When Treating Skin Uncovers the Brain: A Case of Multiple Sclerosis in a Patient on Dupilumab for Atopic Dermatitis
412
The diagnostic challenge between Longitudinal extensive transverse myelitis (LETM) and spinal Dural Arteriovenous Fistula: Importance of Early Diagnosis.
413
HBV Vaccine response following anti-CD20 therapies in Multiple Sclerosis
414
Choroid plexus volume predicts progression independent of relapse activity in early relapsing multiple sclerosis
415
Brain and cognitive age in multiple sclerosis: the role of brain and cognitive reserve.
416
The Perception of Disability in Multiple Sclerosis: Validation and Psychometric Properties of the Italian Perceived Disability Scale
417
Cerebral and Spinal Cervical Cord atrophy rates in a cohort of patients with Multiple Sclerosis on Ocrelizumab: a retrospective study
418
Network-based enrichment analysis of differentially methylated regions in pediatric multiple sclerosis reveals key regulators of immune response and Epstein-Barr virus infection
419
Differentially expressed miRNAs in Multiple Sclerosis patients stratified for NEDA status
420
The evolution of the Italian Multiple Sclerosis and Related Disorders Register: a 2015-2025 journey under the lens of data quality
421
Past 80, Not Past NMOSD: A Case of Posterior ON
422
Successful switch to Ofatumumab after loss of efficacy of Ocrelizumab in multiple sclerosis: a case report
423
Asymptomatic ozanimod-related macular edema: a case report.
424
CASPR2 Antibody-Associated Limbic Encephalitis Presenting with Hyponatremia, Radicular Pain, and Urinary Retention: A Case Report
425
Pregnancy and Infant Outcomes in Women with Relapsing Multiple Sclerosis Following Exposure to Ofatumumab: Update from the PRIM Study
426
Satralizumab for the treatment of neuromyelitis optica spectrum disorders: a single center real life experience
427
Transorbital sonography for evaluation of optic nerve and its vascularization in multiple sclerosis: a correlation study with clinical variables and visual evoked potentials.
428
Pregnancy and family planning: Italian real world data in women with multiple sclerosis receiving Ocrelizumab
SCLEROSI MULTIPLA 5
23
661
HPV Infections in Patients with Multiple Sclerosis: a monocentric study
662
Comparison of STRATIFY JCV and IMMUNOWELL JCV Assays for Anti-JCV Antibody Detection: A Multicenter Study Across Tuscan Neurology Centers
663
Concurrent Management of Multiple Sclerosis and Hairy Cell Leukemia with Cladribine
665
Full remission of Marburgâ€â€like MS after steroids, plasma exchange and Ocrelizumab treatment: a case report
666
Coexistence of Facioscapulohumeral Muscular Dystrophy and Multiple Sclerosis: Clinical Experience with Anti-CD20 Therapy
667
Anti-RI–Associated Paraneoplastic Syndrome in Breast Cancer and Multiple Sclerosis: An Unusual Comorbidity
668
Long-term follow-up study of chronic pain in a cohort of patients with Multiple Sclerosis: preliminary results
669
Long-term Treatment Effect of Frexalimab on NfL and Plasma Biomarkers of Adaptive and Innate Immunity
670
Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety and Efficacy Profile in Recently Diagnosed Treatment-Naive People Living With Relapsing Multiple Sclerosis
671
Over 7 Years, the Risk of Serious Infections Remained Low With Long-Term Ofatumumab Treatment in People With Relapsing Multiple Sclerosis
672
Two-year OCT follow up in Ofatumumab patients shows retinal preservation over non-antiCD20 treatments in Multiple Sclerosis
673
Real-World Effectiveness of Cladribine in Multiple Sclerosis: An Age-Stratified Analysis
674
Long-term effectiveness and safety of ocrelizumab: a single centre real-world study
675
Time to vaccination after rituximab (RTX) discontinuation in patients with anti–aquaporin–4 antibody–positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): A post-hoc analysis of the CHAMPION-NMOSD trial
676
Health Literacy and Unmet Needs in People with Multiple Sclerosis: An Observational Cross sectional Study
677
Neutropenia During Ocrelizumab and Ofatumumab Treatment in Multiple Sclerosis: A Case Series
678
Real-world efficacy and safety of Ofatumumab for the treatment of highly active Multiple Sclerosis: the San Raffaele Hospital single-centre experience.
679
Real-World Safety and Effectiveness of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Observational Study
680
Baseline Characteristics in the Tolebrutinib Phase 3 Primary Progressive Multiple Sclerosis PERSEUS Clinical Trial
681
Patterns and Clinical Implications of Neurogenic Bowel Dysfunction in Multiple Sclerosis
682
Validation of the BIOS-MS Scale: A Psychometric Tool for Assessing Knowledge, Attitudes, and Informational Needs About Biosimilars in People with Multiple Sclerosis
683
Isolated Prosopagnosia in Multiple Sclerosis: A Case Study
684
Psychiatric symptoms in Multiple Sclerosis: prevalence and trajectories in a cohort of people with newly diagnosed MS
SCLEROSI MULTIPLA 6
20
686
Exploring Artificial Intelligence Literacy and Quality of Life in Patients with Multiple Sclerosis: A Cross-Sectional Study
687
Evaluating relapse knowledge in patients affected by Multiple Sclerosis: a cross-sectional study
688
Stratify and ImmunoWELL JCV tests performances in a real-world Multiple Sclerosis cohort: are we really optimizing healthcare resources allocation using biosimilar Natalizumab?
689
Role of Anti-CD20 Monoclonal Antibodies in the Modulation of T Cells in People with Multiple Sclerosis
690
Malignant melanoma development during ocrelizumab treatment in patients with relapsing remitting multiple sclerosis: a case series
692
Early Warning Signs: The Role and Predictive Value of Prodromal Symptoms in Diagnosis of Multiple Sclerosis
693
Siponimod Effectiveness and Safety in Secondary Progressive Multiple Sclerosis in a real-world setting
694
OCT and OCT angiography in differential diagnosis of MS: the retina as a window on the CNS
695
C.AL.M. COPING, ALEXITHYMIA AND MINDFULNESS: AN INNOVATIVE USER-FRIENDLY PSYCHOLOGICAL INTERVENTION FOR MS
696
NMO SPOTLIGHT Registry: Real-World Clinical Outcomes With Eculizumab and Ravulizumab in Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
697
AI-detected brain atrophy pattern associated with Progression Independent of Relapse Activity in Multiple Sclerosis
698
Refining prognosis in adult-onset multiple sclerosis: insights from a systematic review
699
Frailty Predicts Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Study
700
Effectiveness and Bone Marrow Impact of Ofatumumab in Italian RRMS Patients: the ITAKOS Study
702
Agreement analysis of the Italian Multiple Sclerosis and Related Disorders Register for the evaluation of treatment safety in multiple sclerosis: study protocol
703
BURDEN IN OPTIC NEURITIS AMONG PATIENTS WITH DEMYELINATING DISORDERS: A LITERATURE REVIEW - THE ON-COLOUR STUDY
705
Medulloblastoma development in a young man with relapsing-remitting multiple sclerosis: a case report
707
Accuracy of central vein sign in multiple sclerosis diagnosis: a systematic review and Bayesian meta-analysis
708
Cross-sectional and longitudinal observational study on the prevalence and progression of markers of inflammation and fatigue in a cohort of patients with Multiple Sclerosis
709
Cannabinoids for symptomatic treatment for people with multiple sclerosis: the MS Centre of Fidenza experience
SISTEMA NERVOSO VEGETATIVO e SONNO
17
859
Dexmedetomidine in autonomic hyperactivity states: management of two benzodiazepine-refractory cases in Neurology Unit
860
Myocardial 123I-MIBG scintigraphy in pure autonomic failure: a systematic review
862
Isolated Autonomic Failure and Myoclonus as CASPR-2/VGKCs-antibodies paraneoplastic disorder in metastatic splenic relapse of advanced stage of malignant thymoma.
863
A case of seropositive Autoimmune Autonomic Ganglionopathy treated with rituximab: case report and review of literature
864
Seronegative encephalitis in a patient with follicular B-cell non-Hodgkin's lymphoma: possible complication related to Obinutuzumab.
865
Beyond AHI: Phenotypic Stratification of Sleep-Disordered Breathing in Obese Women
866
CSF Lactate Levels in Isolated REM Sleep Behavior Disorder
867
Silent Echoes of the Day: Dream content analysis in Amyotrophic Lateral Sclerosis
868
Profiling OSAS patients of the OSAREDS study database
869
Daridorexant in the Treatment of Chronic Insomnia in Older adults: Real-World Data from a Retrospective Observational Study
870
Beyond the Urge to Move: Exploring Impulsivity, Aggression and Impulse Control Disoders in Restless Legs Syndrome
871
Chronic pain in individuals with Idiopathic Rapid Eye Movement Sleep Behaviour Disorder: a multi-center study
872
Cataplexy Secondary to Brain Lesions: A Systematic Review and Case Report of Pontine Infarction
874
Baseline Subjective Sleep Evaluation in patients with basal-ganglia stroke and its association with outcome
875
SELENE– A Study of the Prevalence of Insomnia in Neurology Outpatient Clinics promoted by the SINsonnia Commettee
876
Sleep Disorders in Adults with Epilepsy: Prevalence and Self-Reported Assessment at a Tertiary Center
877
Frequency of Non-Motor Symptoms in Patients with Idiopathic REM Sleep Behavior Disorder
Carica Qrcode
Vota poster